Circulating microparticles and central blood pressure according to antihypertensive strategy by Massunaga, Nayara D. et al.
Circulating microparticles and central blood pressure
according to antihypertensive strategy
Nayara D. Massunaga0000-0000-0000-0000 ,I,# Carolina N. Franc¸a0000-0000-0000-0000 ,I,II,# Henrique T. Bianco0000-0000-0000-0000 ,I Carlos E.S. Ferreira,I,III
Juliana T. Kato0000-0000-0000-0000 ,I Rui M.S. Po´voa0000-0000-0000-0000 ,I Antonio M. Figueiredo Neto,IV Maria Cristina O. Izar0000-0000-0000-0000 ,I
Francisco Antonio Helfenstein Fonseca0000-0000-0000-0000 I,*
IDepartamento de Medicina, Universidade Federal de Sao Paulo (UNIFESP), Sao Paulo, SP, BR. IIUniversidade Santo Amaro (UNISA), Sao Paulo, SP, BR.
IIIHospital Israelita Albert Einstein, Sao Paulo, SP, BR. IV Instituto Nacional de Ciencia e Tecnologia de Fluidos Complexos, Universidade Sao Paulo,
Sao Paulo, SP, BR.
Massunaga ND, Franc¸a CN, Bianco HT, Ferreira CES, Kato JT, Po´voa RMS, et al. Circulating microparticles and central blood pressure according to
antihypertensive strategy. Clinics. 2019;74:e1234
*Corresponding author. E-mail: fahfonseca@terra.com.br
#Both authors contributed equally to this study and should be considered as first authors.
OBJECTIVES: This prospective, randomized, open-label study aimed to compare the effects of antihypertensive
treatment based on amlodipine or hydrochlorothiazide on the circulating microparticles and central blood
pressure values of hypertensive patients.
METHODS: The effects of treatments on circulating microparticles were assessed during monotherapy
and after the consecutive addition of valsartan and rosuvastatin followed by the withdrawal of rosuvastatin.
Each treatment period lasted for 30 days. Central blood pressure and pulse wave velocity were measured at
the end of each period. Endothelial, monocyte, and platelet circulating microparticles were determined by
flow cytometry. Central blood pressure values and pulse wave velocity were recorded at the end of each
treatment period.
RESULTS: No differences in brachial blood pressure were observed between the treatment groups throughout
the study. Although similar central blood pressure values were observed during monotherapy, lower systolic and
diastolic central blood pressure values and early and late blood pressure peaks were observed in the amlodipine
arm after the addition of valsartan alone or combined with rosuvastatin. Hydrochlorothiazide-based therapy
was associated with a lower number of endothelial microparticles throughout the study, whereas a higher
number of platelet microparticles was observed after rosuvastatin withdrawal in the amlodipine arm.
CONCLUSIONS: Despite similar brachial blood pressure values between groups throughout the study, exposure
to amlodipine was associated with lower central blood pressure values after combination with valsartan,
indicating a beneficial interaction. Differences between circulating microparticles were modest and were mainly
influenced by rosuvastatin withdrawal in the amlodipine arm.
KEYWORDS: Endothelial Microparticles; Monocyte Microparticles; Platelet Microparticles; Central Blood
Pressure; Hydrochlorothiazide; Amlodipine.
’ INTRODUCTION
Arterial hypertension is responsible for high morbidity
and mortality rates around the world. After the publica-
tion of the 2017 American College of Cardiology (ACC)/
American Heart Association (AHA) blood pressure guide-
lines, a substantial increase in the number of hypertensive
adults eligible for drug therapy is expected (1).
Hypertension is a progressive and complex disease that is
associated with anatomical and functional changes in blood
vessels, such as endothelial dysfunction, inflammation, and
disturbance in adaptive and innate immunity (2-4). Indeed,
antihypertensive drugs have been widely used to achieve
appropriate blood pressure levels and prevent comorbidities
(5-8).
Blood pressure monitoring is essential for the treatment
of hypertension. However, the assessment of peripheral
blood pressure may be insufficient to achieve better control
of this complex disease. Thus, the measurement of vascular
compliance and central blood pressure can provide impor-
tant information to expand the possibilities of clinical treat-
ment (9-11).
In addition to these measurements, endothelium-, platelet-,
and monocyte-derived microparticles have been proposed as
novel vascular biomarkers because they have been related to
endothelial erosion, thrombosis, and atherosclerosis (12-14).DOI: 10.6061/clinics/2019/e1234
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Some differences in microparticle concentrations have been
described in relation to the use or withdrawal of statins (15).
Thus, considering the high cardiovascular risk of many
hypertensive individuals, the analysis of the concomitant
use of statins, even in patients with adequate blood pressure
control, seems relevant.
In the ACCOMPLISH study (16), subjects with similar
blood pressure control received combined antihyperten-
sives based on two different strategies, and the difference in
cardiovascular outcomes highlighted the relevance of the
effects of these drugs on vascular biology (17,18). Further-
more, central blood pressure responses to therapy may
differ from peripheral blood pressure responses, thus
explaining some differences in cardiovascular outcomes,
as described in the Conduit Artery Function Evaluation
(CAFE) study (19,20).
The present study aimed to compare the effects of an
antihypertensive treatment based on amlodipine or hydro-
chlorothiazide on circulating endothelium-, monocyte-, and
platelet-derived microparticles and central blood pressure
parameters. Thus, new aspects of antihypertensive therapy
that might be related to different clinical outcomes are des-
cribed here, as reported in the ASCOT and ACCOMPLISH
studies.
’ MATERIALS AND METHODS
Ethics
This prospective, randomized, open-label trial with blin-
ded endpoints complied with the Declaration of Helsinki and
was approved by the Ethics Committee of UNIFESP. Patients
were invited to participate and were included in the trial
after they agreed to the study protocol and signed a written
informed consent form.
Study population
Adult hypertensive patients (aged 40-75 years, of both
sexes) were enrolled if they had systolic blood pressure
(SBP) or diastolic blood pressure (DBP) in the ranges of
160-179 and/or 100-119 mmHg, respectively, without phar-
macological treatment; or 140-159 and/or 90-99 mmHg,
respectively, or appropriate blood pressure levels (o140
and/or o90 mm Hg) with the use of two antihypertensive
drugs. The key exclusion criteria were as follows: second-
ary hypertension, prior coronary heart disease or stroke,
estimated glomerular filtration rate less than 30 mL/min
per 1.73 m2 of body-surface area, history of neoplasm in the
last five years, or active liver disease.
The trial was designed to compare the effects of antihy-
pertensive treatments (strategy: 30 successive days) based
on hydrochlorothiazide (Cloranas; Sanofi Aventis Pharma,
25 mg daily) or amlodipine (Amlocors, Torrent Pharma,
5 mg daily) on circulating microparticles. At baseline, all
subjects received nutritional counseling, and those using
lipid-lowering drugs suspended their use. The first period
of monotherapy (hydrochlorothiazide or amlodipine) was
followed by the addition of valsartan (Brasarts, Torrent
Pharma; 160 mg daily) and rosuvastatin (Rosucors, Torrent
Pharma; 20 mg daily), and the withdrawal of rosuvastatin
with the maintenance of the antihypertensive drugs was
performed in the last 30 days of treatment. Central blood
pressure and pulse wave velocity (PWV) were also measured
at the end of each 30-day treatment (Figure 1).
Circulating microparticles
Circulating endothelium-, monocyte- and platelet-derived
microparticles were measured as previously reported (21,22).
In brief, blood samples were collected and centrifuged
(160g; 20-22oC; 10 min) to obtain platelet-rich plasma
(PRP). The PRP was centrifuged (1500g; 20-22oC; 6 min)
to obtain platelet-poor plasma (PPP). Furthermore, PPP
(50 mL) was labeled (20 min; room temperature) with
CD51FITC, CD42FITC and CD31 PE, and CD14FITC (BD
Biosciences) for the identification of endothelial, platelet,
and monocytic microparticles, respectively. Isotypes (BD
Biosciences) were used as controls. Microparticles were
quantified per microliter of PPP injected into the cyt-
ometer, according to the standard protocol. TruCOUNT
(BD Biosciences) tubes containing a known number of
beads were used to quantify the number of microparticles
per microliter of PPP.
Pulse wave velocity and peripheral and central
blood pressure
Ambulatory blood pressure, central blood pressure, and
PWV were recorded for 24h at the end of each treatment
period using a Dyna-MAPA Plus (Cardios, Brazil) (23).
Statistical Analysis
Data are expressed as the mean (± standard deviation)
or median (and interquartile range) for continuous vari-
ables, and n (%) is used for categorical variables. The
Kolmogorov-Smirnov test was used to evaluate normality.
Continuous variables that were normally distributed were
evaluated by ANOVA-GLM. Microparticles were compared
(within group and between groups) using the Friedman
and Mann-Whitney (nonparametric) tests, respectively.
SPSS software (v. 18.0) was used for statistical analysis.
A significance level of an alpha risk less than 5% was
adopted for all tests.
’ RESULTS
Population
Female, elderly, and overweight individuals (n=46) were
more prevalent in the sample. Table 1 shows the major
baseline characteristics of the study population. The phar-
macological therapies were well tolerated, and no serious
adverse events were recorded in either group. Both groups
had similar blood pressure values at baseline and after
4 weeks of monotherapy with amlodipine (AMLO) or hydro-
chlorothiazide (HCTZ) (Table 2).
Biochemical parameters
No changes in glucose or creatinine serum levels were
observed throughout the study. After a 4-week exposure
to rosuvastatin (V4), a significant and similar decrease was
observed in serum levels of total cholesterol and LDL-C in
both groups (po0.0001 vs. V2, V3, and V5) (Table 3).
Brachial blood pressure
Brachial blood pressure was measured in both groups
(AMLO and HCTZ) and showed similar values for SBP and
DBP at each medical visit. However, higher values were
observed at V2 in both arms. Differences within and between
groups can be calculated from the data shown in Table 2.
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Central blood pressure
Central blood pressure was monitored for 24h from V2 to
V5 in eight patients in the AMLO and HCTZ groups. The
mean values obtained were similar to those obtained at V2.
In the HCTZ arm, no difference between medical visits was
observed in the central SBP or DBP values throughout the
study. However, lower central blood pressure was recorded
beginning at V3 in the AMLO arm. PWV values did not
change during the study, and similar results were recorded in
both groups at each visit from V2 to V5. Central blood
pressure values are shown in Table 4.
Circulating microparticles
The AMLO-based treatment did not change plasma
concentrations of monocyte-derived microparticles (MMP)
or endothelium-derived microparticles (EMP) throughout
the study. However, more platelet-derived microparticles
(PMP) were observed at visit 5 after rosuvastatin with-
drawal (Friedman test; p=0.045). Regarding the HCTZ-
based treatment, no difference was observed in the amount
of circulating PMP or MMP throughout the study, except
for a lower number of EMP at V5 (Friedman test; p=0.001).
Higher levels of MMP (visit 2) and PMP (visit 5) were
Table 1 - Baseline characteristics of the study population receiving treatment based on amlodipine (AMLO) or hydrochlorothiazide
(HCTZ).
Characteristics (mean±SE unless otherwise stated) HCTZ (n=22) AMLO (n=24)
Age (years)* 63 (56-69) 66 (60-71)
Female sex** 21 (95) 21 (87)
Diabetes** 9 (39) 11 (46)
BMI (kg/m2) 29.3±1.1 32.1±1.4
SBP (mm Hg) 133±2 133±2
DBP (mm Hg) 81±2 78±2
Antihypertensives prior to randomization**
None 2 (9) 1 (4)
One 4 (18) 6 (25)
Two 16 (73) 17 (70)
Lipid-lowering therapy (statins) 14 (64) 19 (79)
*median (interquartile range); **n (%); n: number; SE: standard error; BMI: body-mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure;
LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol. No difference was observed between groups regarding baseline
characteristics (unpaired t or Pearson’s chi-square test).
Figure 1 - Study design. Eligible hypertensive subjects were randomized to receive amlodipine (5 mg daily) or hydrochlorothiazide
(25 mg daily) for 4 weeks (V1), followed by three consecutive 4-week periods of treatment with the addition of valsartan (V2) and
rosuvastatin (V3) and the withdrawal of rosuvastatin (V4) in both study arms. Blood samples for measurement of circulating
microparticle concentrations and central blood pressure levels were obtained at the end of each treatment period. The use of
antihypertensive and lipid-lowering drugs was suspended in V1 when monotherapy with either hydrochlorothiazide or amlodipine
was initiated.
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observed in the AMLO group (Mann-Whitney test; p=0.011
and p=0.003, respectively). Table 5 shows the number of
circulating microparticles at each visit and differences
between treatment groups. Figure 2 shows the effects of
amlodipine- or hydrochlorothiazide-based therapies on the
circulating levels of microparticles throughout the study.
’ DISCUSSION
The study revealed that amlodipine- or hydrochlorothia-
zide-based antihypertensive therapies may have different
effects on circulating microparticles. Furthermore, although
central blood pressure values were similar during mono-
therapy, differences in central blood pressure parame-
ters were noted after the addition of valsartan and/or
rosuvastatin (not detected by brachial blood pressure
measurements).
Circulating microparticles, also called extracellular vesicles
or shedding vesicles, are released from the endothelium,
platelets, and many other cells and may have physiological
or pathological effects (24). The diameters of circulating
microparticles are usually in the range of 100-500 nm, and an
elevated number of circulating microparticles has been
reported in many pathological conditions and in subjects
with uncontrolled hypertension (25), acute myocardial
infarction (26), or chronic kidney disease (27).
The first interesting finding of the study was related
to MMP. During monotherapy, the four-week exposure
to amlodipine was associated with higher levels of MMP
than those associated with hydrochlorothiazide exposure,
although in both groups, the brachial blood pressure values
were higher than the recommended value range, which was
expected because the majority of participants in both arms
were previously treated by two antihypertensive agents.
Table 3 - Biochemical characteristics (mean± standard error) by visit and treatment based on hydrochlorothiazide (HCTZ, 25 mg) and
amlodipine (AMLO, 5 mg).
Parameters (mg/dL) Visits HCTZ (N=22) AMLO (N=24) p-values*
Glycemia V2 110 (6) 121 (9) 0.75
V3 118 (13) 106 (9) 0.42
V4 108 (14) 116 (13) 0.71
V5 104 (13) 114 (9) 0.28
Creatinine V2 0.61 (0.03) 0.65 (0.03) 0.36
V3 0.67 (0.04) 0.60 (0.04) 0.27
V4 0.63 (0.06) 0.62 (0.05) 0.85
V5 0.62 (0.06) 0.57 (0.05) 0.78
Cholesterol V2 270 (19) 232 (11) 0.79
V3 233 (20) 217 (12) 0.46
V4 145 (14) 145 (9) 0.99
V5 220 (24) 219 (17) 0.74
LDL-C V2 123 (23) 137 (12) 0.21
V3 127 (17) 129 (10) 0.91
V4 78 (9) 67 (7) 0.37
V5 133 (17) 132 (14) 0.81
HDL-C V2 48 (2) 57 (3) 0.77
V3 46 (2) 53 (4) 0.22
V4 42 (4) 51 (4) 0.10
V5 41 (4) 49 (4) 0.07
Triglycerides V2 287 (72) 198 (59) 0.67
V3 207 (30) 162 (31) 0.33
V4 129 (19) 130 (25) 0.99
V5 247 (47) 199 (70) 0.69
*Between groups. V2 (monotherapy: hydrochlorothiazide or amlodipine); V3 (valsartan, 160 mg added in both arms); V4 (rosuvastatin, 20 mg, added in
both arms); V5 (rosuvastatin withdrawal in both arms).
Table 2 - Brachial systolic and diastolic blood pressure levels (mmHg; median and interquartile range) as measured at the visits after
treatment with hydrochlorothiazide (HCTZ, 25 mg) or amlodipine (AMLO, 5 mg).
Visits Brachial BP HCTZ N=22 AMLO N=24 p-values
V1 sBP 131 (127-138) 132 (126-139) 0.89
dBP 78 (69-87) 81 (75-88) 0.35
V2 sBP 143 (133-151) 142 (133-149) 0.59
dBP 81 (75-80) 85 (80-91) 0.21
V3 sBP 121 (115-127) 127 (113-139) 0.22
dBP 75 (71-80) 74 (68-80) 0.43
V4 sBP 123 (119-130) 122 (113-130) 0.88
dBP 74 (69-79) 73 (70-78) 0.65
V5 sBP 122 (114-130) 126 (117-134) 0.40
dBP 75 (70-79) 77 (73-80) 0.40
V1: screening; V2: monotherapy: hydrochlorothiazide or amlodipine; V3: valsartan, 160 mg, added in both arms; V4: rosuvastatin, 20 mg, added in both
arms; V5: rosuvastatin was withdrawn in both arms. sBP: systolic blood pressure; dBP: diastolic blood pressure. The Mann-Whitney U test was used for
comparisons.
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Elevated MMP values were previously reported in hyper-
tensive subjects with type 2 diabetes, particularly among
those with high SBP (28). In addition, the higher titers of
MMP in the amlodipine arm may be related to harmful
effects on endothelial cells because MMP contains interleukin
1-beta (IL-1b), a cytokine that activates the inflammatory
cascade related to cardiovascular disease (29,30). Hydro-
chlorothiazide decreases blood pressure but not the levels of
high-sensitivity C-reactive protein, even when combined
with valsartan, an angiotensin II blocker (ARB) with anti-
inflammatory properties (31). Interestingly, hydrochlorothia-
zide seems to neutralize the benefits of renin-angiotensin
system blockade in the context of experimental atherosclero-
sis (32). The amounts of circulating EMP were similar in
both antihypertensive therapy arms, but lower levels
were observed throughout the study in the HCTZ group.
Table 4 - Central blood pressure levels (mmHg; median and interquartile range) and pulse wave velocity (PWV, m/s; median and
interquartile range) by visit and treatment based on hydrochlorothiazide (HCTZ, 25 mg) and amlodipine (AMLO, 5 mg).
Visits Parameters HCTZ (n=8) AMLO (n=8) p-values
V2 HR 73 (69-71) 74 (70-78) 0.833
cSBP 109 (106-118) 116 (109-131) 0.430
cDBP 76 (72-81) 73 (69-81) 0.461
AIx75 31 (23-35) 37 (31-39) 0.102
CO 3.9 (3.6-4.2) 3.9 (3.8-4.1) 0.959
P1 101.5 (94.7-104.9) 98.9 (93.2-111.1) 0.916
P2 109.7 (105.5-117.8) 115.8 (109.9-131.9) 0.401
PWV 8.77 (8.13-9.98) 9.94 (7.93-10.25) 0.600
V3 HR 78 (68-92) 74 (69-85) 0.923
cSBP 118 (110-119) 105 (100-111) 0.012*
cDBP 75 (72-82) 64 (61-80) 0.074
AIx75 32.2 (26.7-37.5) 36.6 (28.4-41.9) 0.370
CO 4.12 (3.78-4.55) 3.62 (3.34-4.55) 0.167
P1 105.9 (98.2-106.6) 90.6 (84.3-99.1) 0.027*
P2 118.1 (109.9-118.5) 105.1 (99.6-111.1) 0.012*
PWV 9.07 (8.38-10.05) 9.77 (7.85-9.98) 0.700
V4 HR 72 (71-81) 68 (67-85) 0.757
cSBP 112 (105-118) 103 (97-106) 0.009*
cDBP 73 (72-73) 66 (58-75) 0.009*
AIx75 29.8 (21.8-41.6) 36.3 (29.3-39.8) 0.200
CO 3.82 (3.57-4.27) 3.41 (3.17-3.89) 0.094
P1 96.9 (94.9-102.7) 88.4 (81.5-94.0) 0.002*
P2 112.4 (104.7-118.2) 102.9 (97.5-106.1) 0.009*
PWV 8.98 (8.33-11.21) 9.57 (7.63-10.03) 0.825
V5 HR 75 (69-81) 72 (66-74) 0.101
cSBP 111 (109-120) 107 (98-111) 0.023*
cDBP 74 (73-78) 64 (58-77) 0.039*
AIx75 35.1 (23.4-35.7) 36.7 (29.7-37.3) 0.791
CO 4.07 (3.98-4.64) 3.41 (3.31-3.70) 0.016*
P1 100.1 (96.7-103.9) 91.0 (81.0-96.6) 0.010*
P2 111.1 (108.6-120.5) 106.9 (98.1-111.2) 0.023*
PWV 8.38 (6.57-8.85) 9.72 (7.84-10.05) 0.266
HR: heart rate (beats/min); cSBP: central systolic blood pressure; cDBP: central diastolic blood pressure; AIx75: heart rate adjusted augmentation index; CO:
cardiac output; P1: early blood pressure peak; P2: late blood pressure peak. V2 (monotherapy: hydrochlorothiazide or amlodipine); V3 (valsartan, 160 mg,
added in both arms); V4 (rosuvastatin, 20 mg, added in both arms); V5 (rosuvastatin withdrawal in both arms). *Significant differences between arms
(Mann-Whitney’s U test).
Table 5 - Levels of circulating microparticles (MPs; mg/dL; median and interquartile range) by visit and treatment based on
hydrochlorothiazide (HCTZ, 25 mg) or amlodipine (AMLO, 5 mg).
Visits MPs HCTZ N=22 AMLO N=24 p-values
V2 MMP 0.00 (0.00-1.71) 2.14 (0.21-4.55) 0.011*
EMP 1.63 (1.11-11.91) 2.09 (0.20-6.46) 0.097
PMP 93.8 (82.0-95.8) 91.7 (88.5-94.7) 0.403
V3 MMP 0.70 (0.00-1.34) 4.11 (1.84-8.48) 0.088
EMP 3.87 (0.79-6.20) 1.37 (0.53-6.16) 0.131
PMP 92.4 (87.1-94.5) 88.9 (71.6-92.7) 0.466
V4 MMP 0.86 (0.00-8.26) 4.71 (0.92-11.73) 0.316
EMP 0.39 (0.22-0.69) 1.03 (0.48-4.18) 0.481
PMP 88.1 (74.7-94.1) 90.2 (83.5-95.4) 0.451
V5 MMP 3.35 (0.43-12.5) 1.79 (0.27-6.17) 0.125
EMP 1.02 (0.40-4.38) 0.69 (0.43-1.27) 0.200
PMP 85.8 (75.0-90.4) 92.9 (87.3-94.9) 0.003*
MMP: monocytic microparticles; EMP: endothelial microparticles; PMP: platelet microparticles. V1 (at screening); V2 (monotherapy: hydrochlorothiazide or
amlodipine); V3 (valsartan, 160 mg, added in both arms); V4 (rosuvastatin, 20 mg, added in both arms); V5 (rosuvastatin withdrawal in both arms). *Higher
number of circulating microparticles in the AMLO group (Mann-Whitney’s U test).
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Conversely, a marginal increase in the levels of PMP was
observed in the AMLO group after discontinuation of
rosuvastatin, even without a change in the values of central
or brachial arterial blood pressures. A similar finding was
observed after discontinuation of rosuvastatin in subjects
with stable coronary heart disease (14), with an increase in
the amount of PMP despite the continuous use of antiplatelet
therapy. Interestingly, not only blood pressure control but
also lipid-lowering therapy may influence the amount of
circulating PMP. Overall, the effects of amlodipine and
hydrochlorothiazide on circulating microparticles seem to be
affected differently by concomitant therapies.
Regarding central blood pressure, our study also showed
differences between the AMLO- and HCTZ-based therapies,
with lower SBP and DBP values in the AMLO-based arm.
Indeed, these differences became apparent only after the
addition of valsartan, suggesting a beneficial interaction
between amlodipine and valsartan, an effect not observed
Figure 2 - Box plots of microparticle concentrations by treatment period (visits, V) and study arm. *indicates significant differences.
Monocytic (A), endothelial (B), and platelet (C) microparticle concentrations after the hydrochlorothiazide-based treatment. Monocytic
(D), endothelial (E), and platelet (F) microparticle concentrations after the amlodipine-based treatment. The concentration of
endothelial microparticles decreased after exposure to hydrochlorothiazide (p=0.001; Friedman test). The concentration of platelet
microparticles increased after withdrawal of rosuvastatin in the amlodipine-based arm (p=0.045; Friedman test).
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with hydrochlorothiazide. A recent study showed that
despite similar brachial blood pressure values, ARBs were
more effective than atenolol for reducing central blood
pressure, indicating their potential benefit for the prevention
of cerebrovascular events (33). Furthermore, a meta-analysis
examining the effects of combined therapies on brachial and
central blood pressures showed that betablockers and
diuretics were less effective in reducing central blood pressure
(34). However, the combined treatment with chlorthalidone
and amiloride was effective in reducing central blood pres-
sure, suggesting possible differences in effectiveness between
diuretics in terms of vascular benefits (35,36).
Aortic augmentation index (AIx) has been recognized as
an indicator of arterial stiffness and wave reflection. Changes
in these parameters and PWV may require long-term expo-
sure to therapies and seem to be related to the choice
of antihypertensive therapy (37). In fact, a meta-analysis
exploring the effects of antihypertensives on AIx and PWV
revealed lower AIx values associated with ARBs compared
to the effects of other antihypertensives. However, the
authors failed to demonstrate a lesser decrease in PWV,
probably due to other concomitant medications, comorbid-
ities, age, and time of drug exposure (38). In our study, the
exposure to combined therapies was only 12 weeks, which
was possibly insufficient for changes involving vascular
remodeling. Differences in AIx values were not observed in
either group, but the wave pressures were lower in the
AMLO group after the addition of valsartan.
Limitations
Our prospective randomized study should be considered a
pilot study. First, we enrolled a relatively small number of
patients and examined the effects of therapies on short-term
outcomes. In addition, we were unable to compare the effects
of the treatments with baseline visits (V1) due to the need to
homogenize treatments via the withdrawal of antihyperten-
sives and statins. However, after 4 weeks of monotherapy
with amlodipine or hydrochlorothiazide, the central and
brachial blood pressures were similar, and changes in
circulating microparticles and central blood pressure were
observed shortly after the addition of ARB or ARB/statin.
These findings may contribute to explaining some intriguing
differences in cardiovascular outcomes in trials of combined
therapies, such as the ACCOMPLISH study, despite similar
brachial blood pressure values achieved, especially among
diabetic patients (39).
Our observations are promising, although they are
preliminary and require confirmation in larger prospective
studies. Exploratory analysis of central parameters and PWV
suggest that new technologies, which allow for the registry
of central blood pressure, vascular compliance, and other
hemodynamic data, are essential for establishing new targets
beyond brachial blood pressure for the long-term treatment
of patients with cardiovascular hypertensive disease.
’ CONCLUSIONS
The amlodipine- or hydrochlorothiazide-based antihyper-
tensive therapy had different effects on circulating micro-
particles and central blood pressure parameters. Despite
similar brachial arterial blood pressures and biochemical
parameters throughout the study, exposure to amlodipine
was associated with lower central blood pressure values after
combination with valsartan, indicating a beneficial interaction.
Differences in the amount of circulating microparticles were
modest but were mainly influenced by rosuvastatin with-
drawal in the amlodipine group.
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